Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Geriatrics
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Geriatrics
    Ginkgo biloba for Prevention of Dementia: A Randomized Controlled Trial - (JAMA)
    Ginkgo Evaluation of Memory Study Fails to Show Benefit in Preventing Dementia in the Elderly - (DGNews)
    Kidney Injury Puts Elders at High Risk for Developing Chronic Kidney Disease - (DGNews)
    Aliskiren Helps Elderly Patients Achieves Blood Pressure Control: Presented at AHA - (DGDispatch)
    Surgical Aortic Valve Replacement in Extremely Elderly Patients Safe and Effective: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - Geriatrics
      The Management of Osteoporosis Among Nursing Home and Long-term Care Patients
      Vision Problems in Older Adults, Part 2
      Reducing the Risk for Falls and Fractures: The Role of Vitamin D in the Elderly
      Vision Problems in Older Adults, Part 1
      Management of Chronic Constipation in the Older Adult

      Webcasts/CME archive

       Recent cases - Geriatrics
        Delayed Diagnosis of Intermittent Mesenteroaxial Volvulus of the Stomach by Computed Tomography: A Case Report
        A Simple Hepatic Cyst with Elevated Serum and Cyst Fluid CA19-9 Levels: A Case Report
        Iatrogenic Post-Intubation Tracheal Rupture Treated Conservatively Without Intubation: A Case Report
        Recognition and Treatment of Serotonin Syndrome
        Is Enoxaparin Injection from the Abdominal Wall Safe in Elderly People?: A Fatal Case of Rectus Sheath Hematoma

        Cases archive
          




        my personal edition > geriatrics > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Galantamine Improves Broad Spectrum of Symptoms in Elderly Patients with Alzheimer's Disease: Presented at AGS

        By Anne Jacobson
        Special to DG News

        WASHINGTON, DC -- May 15, 2002 -- Galantamine appears to produce clinically relevant improvements in cognition, activities of daily living, and behavior compared to placebo in the majority of patients with Alzheimer's disease.

        Jacobo E. Mintzer, MD, of the Medical University of South Carolina in North Charleston, South Carolina, United States, presented these findings here Friday at the annual scientific meeting of the American Geriatrics Society.

        "Galantamine has recently been demonstrated to benefit cognition, activities of daily living, and behavior in patients with Alzheimer's disease," explained Dr. Mintzer. "Therefore a more relevant responder analysis for this drug would therefore need to include effects on any of these parameters."

        To evaluate the overall benefit of galantamine therapy across multiple aspects of illness in patients with Alzheimer's disease, Dr. Mintzer designed a double-blind, randomized study in which patients were assigned to placebo (n=286), galantamine 16 mg/day (n=279), or galantamine 24 mg/day (n=273).

        The response to the cholinesterase inhibitor regimen is often judged primarily on change in cognitive function, as measured by the cognitive sub-scale of the Alzheimer's Disease Assessment Scale (ADAS-cog) or the Mini-Mental Status Examination (MMSE), with improving patients regarded as responders.

        Dr. Mintzer's team developed a composite responder analysis of the percentage of patients who showed improvement relative to baseline. Improvement was judged to be clinically significant at four points or higher above baseline on the Neuropsychiatric Inventory (NPI), four points or greater on the ADAS-cog, or one point or higher above baseline on the Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL) inventory.

        After five months of treatment, a significantly greater number of patients who received galantamine 16 or 24 mg/day (75 percent and 72 percent, respectively) improved in one or more of these domains as compared with patients given placebo (54 percent; pŁ0.001).

        "Our findings indicate a broader clinical response to this drug than has generally been appreciated for cholinesterase inhibitor therapy," Dr. Mintzer concluded.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send